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argeted delivery of viral vectors to specific cell types or certain regions of an organ is an important quest for gene transfer in basic sciences as well as clinical gene therapy (1, 2) . Many gene delivery approaches are based on intravascular administration of vectors to achieve transport of the gene of interest to the target site(s). However, physical forces generated by blood flow impede on efficient gene transfer into endothelial cells and counteract retention of viral particles after local administration at specific sites. In addition, ex vivo gene transfer often has to be adapted to the time constraints and temperature (hypothermia) defined by the need to preserve the organ. Short interaction times with the target cells and hypothermia are conditions that are nonpermissive for viral infections (3) (4) (5) , because they hamper diffusion-limited adsorption of viral vectors to the target cells, which is the first step in the viral entry process. A promising approach to enhance vector particle adsorption is the particles' coupling to magnetic nanoparticles (MNPs) (6) (7) (8) . Importantly, this approach should also allow for the retention of the MNP-virus particle complexes in the vessel lumen under physiological flow conditions through application of magnetic fields.
Cell-based gene therapy is an important alternative to vectorbased delivery of therapeutic genes and gene products to diseased organs. However, cell-based gene therapy and other cell replacement approaches rely on efficient targeting and positioning of genetically modified cells at specific sites within tissues and organs to enable their stable engraftment and restoration of function. In this context, it is an important feature of MNPs that they can be used for magnetic labeling of cells (9) (10) (11) .
Here, we tested the concept of nanoparticle-mediated selective gene transfer and cell positioning. The use of MNPs coupled to lentiviral vectors (LVs) dramatically enhanced viral gene transfer under nonpermissive conditions, like physiological flow conditions. In addition, altered in vivo distribution of systemically administrated LV/MNP complexes was achieved by application of magnetic fields. Importantly, cells transduced with LV/MNP exhibited magnetic behavior and could be magnetically positioned at specific sites of ex vivo-perfused vessels and in in vivo models of arterial injury.
Results
MNP-Assisted Lentiviral Transduction Under Nonpermissive Condi-
tions. To analyze whether magnetic nanoparticles can enhance lentiviral transduction under nonpermissive conditions, we used HIV-derived LVs carrying a CMV promoter-driven eGFP expression cassette. LV particles were incubated with 2 different kinds of nanoparticles: (i) positively charged MNPs [CombiMAG (CM)], which are superparamagnetic nanoparticles with magnetite cores and a coating of strong, positively charged polyethylenimine; and (ii) negatively charged MNPs [Trans-MAG (TM)], with starch as coating and terminal phosphate groups. Initially, we studied virus-binding capacity of these nanoparticles in a range of 2 log-steps (Fig. 1A) . Both types of MNPs exhibited a similar virus-binding capacity with a maximum capacity of more than 75% within 20 min of incubation ( Fig. 1 A) .
In this study we focused on the analysis of MNP-assisted lentiviral transduction under nonpermissive conditions, like hydrodynamic flow forces and low temperature. Both conditions hamper the efficiency of lentivector adsorption to target cells, which is a crucial step in lentiviral infections. First, we focused on MNP-assisted transductions under hydrodynamic flow stress. LV/MNP mixtures were applied to human umbilical vein endothelial cells (HUVECs) while being shaken for 30 min (at room temperature) in the presence of a magnetic gradient field [supporting information (SI) Fig. S1 ]. Three days after LV/TM and LV/CM transduction, strong eGFP expression was observed in the target area at the site of the magnetic gradient field (Fig. 1B) . In contrast, transduction without magnetic nanoparticles under the same conditions resulted only in low-level fluorescence, which was detected throughout the whole cell culture plate (Fig. 1B) .
Next, we analyzed the efficiency of MNP-assisted lentiviral transductions under hypothermic conditions (30 min at 4°C). Hypothermic transduction of HUVECs with LV/TM and LV/CM complexes resulted in strong EGFP fluorescence (Fig.  1C) . As expected, transduction without nanoparticles under the same conditions achieved only low levels of transgene expression (Fig. 1C) . Quantitative real-time PCR analyses of the LV/TMand LV/CM-transduced HUVECs revealed similar copy numbers per cell (see indices in To further analyze the efficiency of MNP-assisted transduction under nonpermissive conditions, a broad set of cells from different species was transduced, including primary rat endothelial cells, murine NIH 3T3 fibroblasts, and porcine skin fibroblasts. In all cell lines analyzed, LV/MNP transduction resulted in efficient transgene expression compared with cells transduced in the absence of MNPs (Fig. S2) .
Analysis of Cellular MNP Uptake. Uptake of LV/TM and LV/CM complexes into endothelial cells was analyzed for 3 different MNP doses (13.8, 138 , and 1,380 pg per cell). Transductions with LV/TM (Fig. 1E Upper) and LV/CM (Fig. 1E Lower) resulted in similar efficiencies, and the levels of transgene expression increased with rising MNP dose (Fig. 1E) . To quantify MNP uptake, transduced cells were analyzed by magnetorelaxometry; that is, the measurement of the initial amplitude of the MNP magnetization decay (12) . The lowest MNP dose analyzed (13.8 pg per cell) resulted in a cellular MNP content of 6 pg per cell and 1 pg per cell for LV/TM and LV/CM, respectively (Fig. 1F) . The amount of nanoparticles per cell increased to 110 pg per cell (LV/TM) and 300 pg per cell (LV/CM) after 1,380 pg per cell was applied (Fig. 1F) . We followed the progress of cellular MNP uptake over a time span of 8 h and found perinuclear accumulation of MNPs already 60-90 min after transduction (Fig. S3A ). In addition, we evaluated the persistence of MNPs by magnetorelaxometry (Fig. S3B) . The MNP content decreased to 10% (half-life Ϸ3 days) of the initial MNP content within 9 days after transduction (Fig. S3B ).
MNP-Assisted Transduction of Mouse Aortas Under Physiological Flow
Conditions. To study MNP-assisted lentiviral transduction of vessels, aortas were isolated and transduced with LV/MNP ex vivo. After application of a magnetic gradient field, aortas were washed, cultured for 6 days, and then analyzed for transgene expression. LV transduction for 30 min at 4°C resulted only in low transgene expression (Fig. S4) . In contrast, the use of LV/MNP complexes significantly enhanced transduction efficiency (Fig. S4) . LV/TM-transduced aortas as well as LV/CMtransduced aortas showed levels of transgene expression similar to those in overnight-infected tissues (Fig. S4) . Thus, magnetic nanoparticles can dramatically increase lentiviral transduction efficiency of vessels under nonpermissive conditions. Next, MNP-assisted targeting of LVs in intact aortas was studied by using an ex vivo flow-loop system that mimics physiological flow conditions (Fig. S5A) . Two magnets were placed at one side of the aorta to deflect LV/MNP complexes from their flow orientation by the magnetic flux density gradient ( Fig. 2A) . The absolute magnetic flux density within the aortas (at 0-to 1-mm distance from the magnets) was calculated by means of numeric field simulation (Fig. S5 B and C) . Fluorescent LV particles containing gag-EGFP fusion proteins (13) were used to demonstrate retention of LV/MNP complexes (Fig. 2B) . Using lentivectors carrying the CMV-EGFP reporter cassette, we analyzed transduction of the endothelium. Directly after perfusion, MNP accumulation was clearly visible at the side of the magnets (Fig. 2C, t ϭ 0) . Only 4% of the virus/MNP complexes remained in the flow system after perfusion, indicating high targeting efficiency. Transgene expression in the aortas was followed over 6 days. Both LV/CM (Fig. 2C) and LV/TM (data not shown) transductions resulted in EGFP expression at the site of the magnetic gradient field. Histological analysis of aortas perfused with LV/TM (Fig. 2D Upper) and LV/CM (Fig.  2D Lower) revealed EGFP expression in the intima layer, as demonstrated by colocalization of the endothelial marker CD31 with EGFP. As controls, aortas were perfused with (i) LV without MNPs, (ii) MNPs without LV, and (iii) LV/MNP complexes without a magnetic gradient field. In none of these controls was EGFP expression observed (data not shown).
MNP-Assisted Transduction of Organs In Vivo-Analysis of Biodistri-
bution. To analyze whether a magnetic gradient field can alter the native in vivo distribution of LVs, we injected LV/CM complexes via catheter into the carotid artery of mice. The number of viral integrants in different organs was determined by using quantitative real-time PCR, which has a high degree of sensitivity, reproducibility, and accuracy in quantifying LV copy numbers in ) (E and F) In vivo distribution of integrated lentivectors after injection into the carotid artery of mice. Shown is the percental distribution (ϮSEM) in different organs (n ϭ 3) of mice that were exposed to a strong magnetic field at the right abdominal wall (F, n ϭ 5) and of control mice (E, n ϭ 3). * , P Ͻ 0.05 compared with the control group. cells and organs (14) (15) (16) . Analyses of control mice 6 days after injection of the LV/MNP complexes (n ϭ 3) revealed the presence of viral integrants predominately in the lung and liver (Fig. 2E) . Placement of a permanent magnet at the right abdominal wall close to the liver (n ϭ 5) resulted in a significant redistribution of LV/MNP complexes toward the liver and, concomitantly, the number of viral integrants in the lung was significantly reduced (Fig. 2F) . Thus, application of an external magnetic field can be used to alter the tissue distribution of MNP-coupled LV particles in vivo.
Positioning of Transduced Cells by Magnetic Fields.
The efficient cellular uptake (Fig. 1F) of MNPs should also render the cells superparamagnetic, and therefore allow their magnet-guided positioning. Initially, magnetic retention of LV/MNPtransduced cells was analyzed by transferring them into reaction tubes with a magnet placed at one side of the tubes (Fig. 3 A-C) . After 15 min, retention of cells close to the magnets was observed for LV/TM-transduced (Fig. 3B) and LV/CMtransduced (Fig. 3C) cells, but not for untreated control cells (Fig. 3A) . After transduction with LV/TM and LV/CM at the highest MNP dose (1,380 pg of MNPs applied per cell), more than 80% of the transduced cells were retained by the magnetic gradient field (Fig. 3D) . Next, we analyzed whether LV/MNPtransduced cells can be positioned in the presence of hydrodynamic flow forces. HUVECs were transduced with and without MNPs, transferred to 6-well plates, and cultured while slowly being shaken, with magnets positioned under the plates (Fig. S1) . As additional controls, LV/TM-and LV/CM-transduced cells also were cultured without magnets below the plates. After 24 h of culture, cells on the plates were stained with sulforhodamine B (Fig. 3E) . In contrast to control cells, LV/MNP-transduced cells (virus ϩ TM and virus ϩ CM) and cells transduced with MNPs alone (TM and CM) were retained in the areas above the magnets (Fig. 3E) . These findings clearly indicate that superparamagnetic nanoparticles can be used to position cells by a magnetic gradient field even in the presence of hydrodynamic forces.
Positioning of Transduced HUVECs to the Intima Under Physiological
Flow Conditions. Next, we studied whether LV/MNP-transduced cells can be positioned to vessel walls; that is, to the native endothelial cell layer. Because we observed higher cell seeding efficiencies and lower adverse effects on cell viability for LV/TM compared with LV/CM-transduced cells (Fig. S6) , we used these MNPs for the following experiments. Aortic strips were incubated with LV/TM-transduced HUVECs while slowly being shaken to induce hydrodynamic forces. After 24 h, strong EGFP fluorescence was observed in aortas cultured in the presence of a magnetic gradient field (Fig. 4A Left) . Aortas that were cultured without a magnet exhibited only marginal EGFP expression (Fig. 4A Right) . The histological analysis using antibodies against human CD31 [platelet endothelial cell adhesion molecule-1 (CD31h)] demonstrated that cells positive for EGFP and human CD31 were found at the luminal surface of the vessel (Fig. 4B) , indicating successful positioning of the transduced HUVECs to the intima layer. A detailed analysis of the fluorescent signals revealed that almost 100% of the EGFP signal was colocalized with human CD31.
To study MNP-assisted cell positioning under more physiological conditions, we used our flow-loop aortic perfusion system (Fig. S5A) . During the perfusion, more than 60% of the LV/ TM-transduced cells were retained at the intima of the aorta in the presence of a magnetic gradient field (Fig. 4C) . Immunohistochemical staining of the perfused aortas with antibodies against human and murine CD31 revealed that the EGFP signals were colocalized with human CD31 (Fig. 4D) . Detailed image analyses revealed a 93% overlap between EGFP and CD31h signals. Interestingly, both signals were located in the endothelial layer (murine CD31) of the aorta (Fig. 4D ). These findings demonstrate that LV/MNP-transduced cells can be positioned to the endothelial layer of perfused vessels.
Positioning of Endothelial Cells to Injured Vessels In Vivo.
To demonstrate the utility of the technology in vivo, we first studied positioning of MNP-labeled cells in noninjured murine vessels. LV/TM-transduced HUVECs were injected into the thoracic aorta (via a catheter) of mice. Small magnets were positioned close to the abdominal aorta or iliac artery. In vessels that were subjected to a magnetic field, we found strong EGFP fluorescence (derived from the LV/MNP-transduced HUVECs) in the areas that were located close to the magnets (Fig. S7) , indicating that intravascular cell positioning by magnetic force is feasible in vivo.
To evaluate the feasibility of our approach in a more clinically relevant setting, we used an in vivo injury model of the mouse carotid artery (17) . Our aim was to position superparamagnetic endothelial cells to the denuded common carotid artery (CCA). For this purpose, 40,000 LV/TM transduced HUVECs were infused via the external carotid artery while small magnets were positioned at the injured CCA. In parallel, control experiments were performed under the same conditions without placing a magnet to the CCA. Retention of MNP-labeled, transgenic HUVECs was analyzed by fluorescence stereomicroscopy (Fig.  4E) and histology (Fig. 4F) . Importantly, fluorescence imaging revealed EGFP expression at the injured vessel walls in the presence of magnets (Fig. 4E, Left) , but not in control mice (Fig.  4E, Right) . Histological analysis corroborated the presence of MNP-labeled, EGFP-expressing cells at the site of the magnetic gradient field (Fig. 4F) . Taken together, MNP-labeled cells can be positioned to the vessel wall in vivo by magnetic force at sites of arterial injury. Our data clearly demonstrate that MNP-assisted lentiviral transduction results in efficient site-directed targeting of the endothelium, indicating that this method has the potential for localized gene therapy in the vascular system. Furthermore, using external magnets we were able to alter the biodistribution of systemically administered MNP-coupled LVs, indicating that organ-specific targeting can be achieved by using magnetic forces in vivo. An important aspect of our study is the combination of targeted delivery of viral vectors with positioning of the transduced cells by using superparamagnetic nanoparticles. Cell positioning is of high relevance for regenerative medicine because cell replacement therapies require the efficient seeding of cells in the diseased organs. Especially, systemically delivered cells must establish contact with the target site and overcome hydrodynamic and shear forces generated by the blood flow until more permanent engraftment is achieved. The uptake of MNPs renders cells superparamagnetic, which can be used to capture MNP-loaded cells by using magnetic forces (9) (10) (11) . In addition, we reasoned that for many applications, genetic engineering of the cells before transplantation is required; for example, to enhance the therapeutic effect by expressing a therapeutic gene in the transplanted cells. Thus, the transplanted cells function also as vehicles for gene transfer. Here, we studied whether LV/MNP-transduced transgenic cells can be targeted to distinct areas of a blood vessel by magnetic forces. This differs from previous studies, where magnetic forces were used to capture and retain magnetically labeled cells on nonphysiological substrates-that is, stents (10) and Dacron or polytetrafluoroethylene grafts (9, 18) . Our data show that MNP-assisted positioning of human endothelial cells can be achieved not only in vessels that were subjected to physiological flow (ex vivo perfusion model), but also in different murine vessels in vivo. Importantly, magnetic cell positioning to the vessel wall was achieved at sites of arterial injury in vivo. These experiments in mice suggest that MNP-based cell positioning might have potential for the development of cell-based therapies aiming at the repair of focal endothelial damage. This strategy appears to be interesting also for cell replacement approaches in other organs, like the heart, because it enables systemic delivery of the cells without invasive surgery and magnet-based, site-restricted positioning. Interestingly, positioning of a relatively low number of cells can have therapeutic effects; for example, the stable engraftment of only a few thousand cardiac progenitors or transgenic skeletal myoblasts strongly reduces the incidence of ventricular arrhythmias after myocardial infarction (19) . Taken together, MNP-assisted lentiviral gene transfer and cell positioning is a promising method for combined gene and cell replacement therapies.
Materials and Methods
All animal experiments were performed in accordance with National Institutes of Health animal protection guidelines and were approved by the local authorities of the University of Bonn.
MNP-Assisted Lentiviral Transduction of Cells. CM and TM nanoparticles were obtained from Chemicell. The standard LV/MNP mixture contained a relative amount of Ϸ50 LVs per cell and Ϸ27.6 pg of MNPs per virus particle (equal to Ϸ1,380 pg of MNPs per cell).
MNP-Assisted Lentiviral Transduction of Aortas.
In a total volume of 800 L of HBSS, 52.5 g of MNPs were incubated with Ϸ1 ϫ 10 8 LVs for 20 min at room temperature. Then, the mixture was applied to the wells, and an NdFeB magnet was placed under the aortas.
Ex Vivo Perfusion of Mouse Aortas. A total of 33.75 g of MNPs was mixed with 1.7 ϫ 10 8 LVs in a total volume of 800 L of HBSS and incubated for 20 min at room temperature. During perfusion, 2 small NdFeB magnets were placed in close proximity to one side of the aorta (Fig. 2 A) .
Magnetic Positioning of HUVECs. LV/MNP-transduced HUVECs were transferred to 6-well plates and placed onto an aluminum plate containing magnets at defined positions (Fig. S1 ). For the positioning of HUVECs to vessels, small aortic squares were previously pinned onto the plates. The complete setup was placed onto a compensator (at 5% CO2) and cultured overnight while being shaken slowly (20 rpm). For the positioning of HUVECs to vessels by ex vivo perfusion, LV/TM-transduced HUVECs were introduced into the perfusion system. Additional Methods. A more detailed description of the methods is provided in the SI Materials and Methods.
